Harry C. Schouten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Harry C. Schouten has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Robert Sydes
Medical Research Council Clinical Trials Unit at UCL, London, UK
2 shared publications Adolfo Porcellini
From the University Hospital Maastricht, Maastricht, and the Erasmus Medical Center, Rotterdam, the Netherlands; Medical Research Council Clinical Trials Unit, London, United Kingdom; Norwegian Radium Hospital, Oslo, Norway; Ospedale P.F. Calvi, Noale, Italy; University Hospital of Uppsala, Sweden; Herlev University Hospital, Copenhagen, Denmark
1 shared publicationAndrea Jox
Department of Internal Medicine, University of Cologne, Germany
1 shared publicationAnnick Haesevoets
Department of Internal Medicine, University Hospital, Maastricht, The Netherlands
1 shared publicationAnton H. N. Hopman
Department of Molecular Cell Biology and Genetics, University of Maastricht, The Netherlands
1 shared publicationFrans C. S. Ramaekers
Department of Molecular Cell Biology and Genetics, University of Maastricht, The Netherlands
1 shared publication
Latest Publications
- 1 November 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (21) , 3918-3927
High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT) followed by autologous stem-cell transplantation is more effective than standard treatment with regard to progression-free survival (PFS) and overall survival (OS) in patients with relapsed follicular non-Hodgkin’s lymphoma; and to assess the additional value of B-cell purging of the stem-cell graft with regards to PFS and OS.
- 1 November 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (21) , 3918-3927
High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial
Purpose: To determine, in a randomized clinical trial, whether high-dose therapy (HDT) followed by autologous stem-cell transplantation is more effective than standard treatment with regard to progression-free survival (PFS) and overall survival (OS) in patients with relapsed follicular non-Hodgkin’s lymphoma; and to assess the additional value of B-cell purging of the stem-cell graft with regards to PFS and OS.
- Open Access
- 1 March 2000
- Published by Elsevier in Annals of Oncology
- Vol. 11 (suppl_1) , S91-S94
The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
Background : The CUP trial was initiated to analyze the value of high-dose therapy and stem-cell transplantation and purging in patients with relapsed chemosensitive follicular NHL. Patients and methods : After three cycles of chemotherapy responsive patients were randomized to either three more cycles of the same chemotherapy (C), high-dose therapy followed by autologous unpurged (U) or purged (P) stem-cell transplantation. Purging was performed using a cocktail of monoclonals. Pretransplant conditioning consisted of cyclo-phosphamide (60 mg/kg×2) and total body irradiation. Results : Of the 140 patients registered from 26 centers in Europe, 89 fulfilled the criteria for randomization (C: 24, U: 33 and P: 32). Reasons for failure to randomize were: no response (28), persistent marrow infiltration (4), patient refusal (7). other (7), no data (5). With the current follow up (median 26 months from randomization) 16 (66%) in C are known to have progressed or relapsed, in contrast to 13 (39%) of U and 12 (37%) of the P patients ( P -value 0.002). Overall survival is premature with the current available data. Conclusions : Patients in U and P arms had higher progression/relapse-free survival rate. There are some suggestions of some improvement in overall survival rate.
- 1 March 2000
- Published by Elsevier in Annals of Oncology
- Vol. 11 (suppl_1) , S91-S94
Open AccessThe CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
Background : The CUP trial was initiated to analyze the value of high-dose therapy and stem-cell transplantation and purging in patients with relapsed chemosensitive follicular NHL. Patients and methods : After three cycles of chemotherapy responsive patients were randomized to either three more cycles of the same chemotherapy (C), high-dose therapy followed by autologous unpurged (U) or purged (P) stem-cell transplantation. Purging was performed using a cocktail of monoclonals. Pretransplant conditioning consisted of cyclo-phosphamide (60 mg/kg×2) and total body irradiation. Results : Of the 140 patients registered from 26 centers in Europe, 89 fulfilled the criteria for randomization (C: 24, U: 33 and P: 32). Reasons for failure to randomize were: no response (28), persistent marrow infiltration (4), patient refusal (7). other (7), no data (5). With the current follow up (median 26 months from randomization) 16 (66%) in C are known to have progressed or relapsed, in contrast to 13 (39%) of U and 12 (37%) of the P patients ( P -value 0.002). Overall survival is premature with the current available data. Conclusions : Patients in U and P arms had higher progression/relapse-free survival rate. There are some suggestions of some improvement in overall survival rate.
- 1 December 1999
- Published by Wiley in The Journal of Pathology
- Vol. 189 (4) , 527-532
Morphologically normal, CD30‐negative B‐lymphocytes with chromosome aberrations in classical Hodgkin's disease: the progenitor cell of the malignant clone?
- 1 December 1999
- Published by Wiley in The Journal of Pathology
- Vol. 189 (4) , 527-532
Morphologically normal, CD30‐negative B‐lymphocytes with chromosome aberrations in classical Hodgkin's disease: the progenitor cell of the malignant clone?